Unleash the power of our people

The Promise of Gene Therapy: Investing in the Evolution of Treatments for Rare Diseases

Pfizer is at the forefront of thegene therapy space, with established collaborations, partnerships and acquisitions that bolster our pipeline, and distinct state-of-the-art manufacturing capabilities to bring this next generation of scientific innovation to patients living with rare diseases. We continue to advance key clinical development programs in hemophilia A and B, Duchenne muscular dystrophy and additional pre-clinical research programs. Pfizer currently hasplans to invest up to approximately $800 million at our Sanford and Durham, North Carolina, gene therapymanufacturing facilities. The goal is to expand capacity, strengthen capabilities and supply critical, potentially life-changing medicines by leveraging an in-vivo recombinant adeno-associated virus gene therapy technology platform for patients with rare diseases around the world.
Unleash the power of our people
Deliver first-in-class science
Transform our go-to-market model
Win the digital race in pharma
Lead the conversation